India's Dr Reddy's on track for 3rd weekly drop on semaglutide supply disruption, Q1 profit miss
24/07/2026 10:43
BUZZ-India's Dr Reddy's on track for 3rd weekly drop on semaglutide supply disruption, Q1 profit miss ** Shares of Dr Reddy's REDY.NS down 5% at 1,150.1 rupees so far this week vs 0.4% decline in Nifty Pharma .NIPHARM
** Stock on track for third straight week of losses
** On Wednesday, drugmaker reported Q1 consol net profit fell nearly 70%, missing estimates; consol rev from ops declined 5.5%
** Stock down 4.6% since results
** Co warns semaglutide supply disruptions could weigh on availability in global markets as it pursues regulatory approvals in Brazil, Turkey and Mexico
** Multiple brokerages cut earnings forecasts for drugmaker
** Stock rated "Hold" on average by 38 analysts; median PT at 1,237 rupees - LSEG-compiled data
** YTD, stock down about 9% vs pharma index's 12% rise
(Reporting by Mridula Kumar in Bengaluru)
Recent news on Dr. Reddy's Laboratories
See all newsDr Reddy's rolls out new generic Ozempic brands to ease Obeda supply hit
Dr Reddy's beats quarterly profit estimate on India market lift (updated)
India's Dr Reddy's beats quarterly profit estimate
Brief: Dr. Reddy's Q2 Consol Net PAT 9.25 Billion Rupees
Dr Reddy's rolls out new generic Ozempic brands amid Obeda supply disruption